Expanded Access to ANG1005 for Individual Patients
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
Sponsor: Angiochem Inc
A observational or N/A phase clinical study on Anaplastic Astrocytoma and Anaplastic Oligodendroglioma, this trial is ongoing. The trial is conducted by Angiochem Inc and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Angiochem Inc
For direct contact, visit the study record on ClinicalTrials.gov .